The real-world experience with single agent ibrutinib in relapsed/refractory CLL
| dc.authorid | Mehmet Hilmi Doğu / 0000-0001-7237-2637 | en_US |
| dc.authorscopusid | Mehmet Hilmi Doğu / 55212747300 | |
| dc.authorwosid | Mehmet Hilmi Doğu / W-2255-2017 | |
| dc.contributor.author | Akpınar, Seval | |
| dc.contributor.author | Doğu, Mehmet Hilmi | |
| dc.contributor.author | Çelik, Serhat | |
| dc.contributor.author | Ekinci, Ömer | |
| dc.contributor.author | Yönal Hindilerden, İpek | |
| dc.contributor.author | Dal, Mehmet Sinan | |
| dc.date.accessioned | 2021-10-15T06:13:04Z | |
| dc.date.available | 2021-10-15T06:13:04Z | |
| dc.date.issued | 2021 | en_US |
| dc.department | İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| dc.description.abstract | ntroduction/background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ? grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. | en_US |
| dc.identifier.citation | Akpinar, S., Dogu, M. H., Celik, S., Ekinci, O., Hindilerden, I. Y., Dal, M. S., Davulcu, E. A., Tekinalp, A., Hindilerden, F., Ozcan, B. G., Hacibekiroglu, T., Erkurt, M. A., Bagci, M., Namdaroglu, S., Korkmaz, G., Bilgir, O., Cagliyan, G. A., Ozturk, H., Serin, I., Tiryaki, T. O., … Altuntas, F. (2021). The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. Clinical lymphoma, myeloma & leukemia, S2152-2650(21)02040-1. Advance online publication. | en_US |
| dc.identifier.doi | 10.1016/j.clml.2021.09.010 | en_US |
| dc.identifier.pmid | 34629286 | en_US |
| dc.identifier.scopus | 2-s2.0-85116827763 | en_US |
| dc.identifier.scopusquality | N/A | en_US |
| dc.identifier.uri | https://doi.org/10.1016/j.clml.2021.09.010 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12713/2150 | |
| dc.identifier.wos | WOS:000760119700011 | en_US |
| dc.identifier.wosquality | Q3 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.institutionauthor | Doğu, Mehmet Hilmi | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.ispartof | Clinical Lymphoma, Myeloma and Leukemia | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Bruton Tyrosine Kinase | en_US |
| dc.subject | Chronic Lymphocytic Leukemia | en_US |
| dc.subject | Ibrutinib | en_US |
| dc.subject | Relapsed/refractory | en_US |
| dc.subject | P53 Mutation | en_US |
| dc.title | The real-world experience with single agent ibrutinib in relapsed/refractory CLL | en_US |
| dc.type | Article | en_US |
